GW7647

265129-71-3

C29H46N2O3S

DMSO : >= 60 mg/mL (119.34 mM)

Cell Cycle/DNA Damage

GW7647 is a potent PPARalpha agonist, with EC₅₀s of 6 nM, 1.1 uM, and 6.2 uM for human PPARalpha, PPARgamma and PPARdelta, respectively. IC50 & Target: EC50: 6 nM (Human PPARalpha), 1.1 uM (Human PPARgamma), 6.2 uM (Human PPARdelta)^[5] In Vitro: GW7647 (1 uM) causes a significant increase of PDZK1 protein expression to 129.7 +/- 6.5% of vehicle treated control in Caco2BBE cells in the absence and presence of IL-1beta. GW7647 also attenuates the IL-1beta-mediated decrease in PDZK1 expression^[1]. GW7647 (50 nM) stimulates the PI3K phosphorylation followed by the Akt (Ser473) phosphorylation, which induces NOS1 phosphorylation increased the amounts of NO released in the stripped antral mucosa. GW7647 (50 nM) enhances the initial phase of Ca²⁺-regulated exocytotic events stimulated by ACh in antral mucous cells, but GW7647 alone does not evoke any exocytotic event. GW7647 plus ACh stimulates the effects of wortmannin (50 nM) and AKT-inh (100 nM) on the exocytotic events in antral mucous cells^[2]. GW 7647 (100 nM) reduces the AQP9 protein abundance by 43%, but it shows not significant effect at 10 and 1, 000 nM in WIF-B9 hepatocytes. GW 7647 (100 nM) causes a 24% reduction in AQP9 protein abundance in HepG2 cells, however, it does not significantly increase the protein abundance of L-FABP in HepG2 hepatocytes^[3]. In Vivo: GW7647 (3 mg/kg per day) does not prevent the development of cardiac hypertrophy, but it prevents the decline in left ventricular ejection fraction in vivo^[4].